DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Sertraline for Alcohol Dependence and Depression

Information source: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alcoholism; Depression

Intervention: naltrexone (Revia) (Drug); sertraline (Zoloft) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Summary

This study will examine depressed alcoholic outpatients to assess whether combining naltrexone (Revia) and sertraline (Zoloft) will result in greater reductions in both drinking and depression over either medication alone or placebo. A secondary aim is to determine whether certain patient features will predict response to sertraline, naltrexone or the combination of the two drugs. Subjects will be randomized into treatment groups for 16 weeks. The followup phase includes two visits at 6 and 9 months after treatment.

Clinical Details

Official title: Sertraline for Alcohol Dependence and Depression

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study

Eligibility

Minimum age: 21 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Current diagnosis of major depression for a 2-week duration following discontinuation

of drinking or prior to study.

- Meets criteria for alcohol dependence.

- Drank a minimum of 48 standard alcoholic drinks prior to treatment (average of 12

drinks/week) on 40% of the 30 days before treatment.

- Able to maintain abstinence for four days with or without the aid of detoxification

medications.

- Lives within 50 miles of the study site.

- Speaks, understands and prints in English.

Exclusion Criteria:

- Ever abused or dependent on opiates or evidence of opiate use in month prior to

treatment.

- Meets criteria for dependence on any substance other than alcohol (except nicotine).

- Tests positive on the urine drug screen at the initial visit.

- Meets criteria for panic, obsessive-compulsive, post-traumatic stress, or eating

disorders.

- Meets current or lifetime criteria for bipolar affective disorder, schizophrenia or

any psychiatric disorder, or organic mental disorder.

- Has evidence of or a history of significant hematological, pulmonary, endocrine,

cardiovascular, renal, or gastrointestinal disease.

- Hepatocellular disease.

- Abnormal elevation in bilirubin.

- Needs treatment with any psychoactive medication including antiseizure medications.

- Current use of disulfiram.

- Has taken a monoamine oxidase inhibitors, serotonin reuptake inhibitor or opiate

antagonist in the month prior to randomization.

- Is or has been taking an investigational drug within one month prior to study.

- Females who are pregnant, contemplating pregnancy in the next six months, nursing or

not using an effective contraceptive birth control method (if relevant).

Locations and Contacts

Treatment Research Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Additional Information


Ending date: April 2004
Last updated: December 18, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009